Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 2166 participants.
Also called NCT04951856
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,166 participants
- Registry
-
NCT04951856 -
2021-000573-80
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04951856. Randomized; no masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2026-05-22 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
- Acronym
- AMUNDSEN
- Condition
- STEMI - ST Elevation Myocardial Infarction
- Condition
- NSTEMI - Non-ST Segment Elevation MI
- Intervention (Drug)
- Evolocumab 140 MG/ML
- Intervention (Drug)
- Standard of care (SOC)
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Action Research Group
- Collaborator
- Amgen
Record details
- Record id
cardio:ct-nct04951856- Content hash
b12c56098b8fc92ef269eb469bd42b17f69114733438e9e21e9ce28b07a0938f